Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of â

doi.org/10.1038/leu.2017.29, hdl.handle.net/1765/108115
Department of Immunology

Flores-Montero, J., Sanoja-Flores, L. (L.), Paiva, B., Puig, N., García-Sánchez, O. (O.), Böttcher, S., … Orfao, A. (A.). (2017). Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 31(10), 2094–2103. doi:10.1038/leu.2017.29